Eleven-Year Trends in Lipid-Modifying Medicines Utilisation and Expenditure in a Low-Income Country: A Study from the Republic of Srpska, Bosnia and Herzegovina

References

• World Health Organisation. Cardiovascular diseases. Fact sheets. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Accessed January 15, 2022.
   Google Scholar
• World Health Organisation. Global health estimates: life expectancy and leading causes of death and disability. Global Health Observatory. Data. Available from: https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates. Accessed January 15, 2022.
   Google Scholar
• World Health Organisation. Cardiovascular Disease. Data and statistics. Available from: https://www.euro.who.int/en/health-topics/non-communicable-diseases/cardiovascular-diseases/data-and-statistics. Accessed January 15, 2022.
   Google Scholar
• World Health Organization. European health for all database 2019; 2019. Available from: http://www.euro.who.int/hfadb. Accessed January 15, 2022.
   Google Scholar
• Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;34976:2982–3021. doi:10.1016/j.jacc.2020.11.010
   Google Scholar
• Milašinović G. National Guide of Clinical Practice for the Diagnosis and Treatment of Lipid Disorders. Belgrade: Accreditation Agency for Health Institutions of Serbia; 2012. Serbian.
   Google Scholar
• Mach F, Baigent C, Catapano AL, et al; ESC Scientific Document Group. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188. doi:10.1093/eurheartj/ehz455
   PubMed Web of Science ®Google Scholar
• Hoover LE. Cholesterol management: ACC/AHA updates guideline. Am Fam Physician. 2019;99(9):589–591. doi:10.1161/CIR.0000000000000452
   PubMed Web of Science ®Google Scholar
• Karr S. Epidemiology and management of hyperlipidemia. Am J Manag Care. 2017;36023(9):S139–S148.
   Google Scholar
• Kalinić D, Škrbić R, Vulić D, et al. Trends in antihypertensive medicine utilisation in the Republic of Srpska, Bosnia and Herzegovina: an eleven-year follow-up. Front Pharmacol. 2022;13:889047. doi:10.3389/fphar.2022.889047
   PubMed Web of Science ®Google Scholar
• Catapano AL, Graham I, De Backer G, et al.; ESC Scientific Document Group. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999–3058. doi:10.1093/eurheartj/ehw272
   PubMed Web of Science ®Google Scholar
• Visseren FL, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Developed by the task force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies. Eur Heart J. 2021;42:3227–3337. doi:10.1093/eurheartj/ehab484
   PubMed Web of Science ®Google Scholar
• Guidelines Committee. Hyperlipoproteinaemia, Guideline for Clinical Practice. Ministry of Health and Social Welfare of the Republic of Srpska; 2004.
   Google Scholar
• Guidelines Committee. Hyperlipoproteinaemia, Guideline for Clinical Practice. Ministry of Health and Social Welfare of the Republic of Srpska; 2008.
   Google Scholar
• Ministry of Health and Social Welfare of Republic of Srpska. Guideline for clinical practice: hyperlipoproteinaemia 2015; 2015. Available from: https://www.vladars.net/sr-SP-Cyrl/Vlada/Ministarstva/MZSZ/Documents/15.%204.%20Hiperlipoproteinemije.pdf. Accessed September 16, 2022.
   Google Scholar
• Nežić L, Škrbić R, Dobrić S, et al. Simvastatin and indomethacin have similar anti-inflammatory activity in a rat model of acute local inflammation. Basic Clin Pharmacol Toxicol. 2009;104(3):185–191. doi:10.1111/j.1742-3837843.2008.00302.x
   PubMed Web of Science ®Google Scholar
• Nežić L, Škrbić R, Amidžić L, Gajanin R, Kuča K, Jaćević V. Simvastatin protects cardiomyocytes against endotoxin-induced apoptosis and up-regulates survivin/NF-κB/p65 expression. Sci Rep. 2018;8(1):14652. doi:10.1038/s41598-018-32376-4
   PubMedGoogle Scholar
• Republic of Srpska Institute of Statistics. Demographic Statistics. Statistical Yearbook 2020; 2020. Available from: http://www.rzs.rs.ba/. Accessed January 16, 2022.
   Google Scholar
• Marković PV, Škrbić R, Godman B, Gustafsson LL. Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions. Expert Rev Pharmacoecon Outcomes Res. 2012;12:661–671. doi:10.1586/erp.12.48
   PubMed Web of Science ®Google Scholar
• Health Insurance Fund of Republic of Srpska. Drug lists. Available from: https://www.zdravstvo-srpske.org/files/cjenovnici/lijekovi.pdf. Accessed February 12, 2022.
   Google Scholar
• Health Insurance Fund of Republic of Srpska. The rights of the insured; 2021. Available from: https://www.zdravstvosrpske.org/files/regulativa/osig/Pravilnik%20o%20son%20ostvarivanja%20prava%20na%20zz.PDF. Accessed January 18, 2022.
   Google Scholar
• World Health Organization. Introduction to Drug Utilisation Research. WHO International Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug Statistics Methodology, WHO Collaborating Centre for Drug Utilisation Research and Clinical Pharmacological Services; 2003. Available from: https://apps.who.int/iris/bitstream/handle/10665/42627/924156234X.pdf. Accessed January 16, 2022.
   Google Scholar
• Public Health Institute of Republic of Srpska. Analysis of population health in Republic of Srpska, 2019 and 2020. (in Serbian language) Available from: https://www.phi.rs.ba/pdf/publikacije/Izvjestaj%20o%20potrosnji%20lijekova%20za%202019.%20i%202020.%20godinu.pdf. Accessed January 15, 2022.
   Google Scholar
• Godman B, Wettermark B, van Woerkom M, et al. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. Front Pharmacol. 2014;5:106. doi:10.3389/fphar.2014.00106
   PubMed Web of Science ®Google Scholar
• Marković PV, Škrbić R, Petrović A, et al. Polypharmacy among the elderly in the Republic of Srpska: extent and implications for the future. Expert Rev Pharmacoecon Outcomes Res. 2016;16:609–618. doi:10.1586/14737167.2016.1115347
   PubMed Web of Science ®Google Scholar
• OECD. Health at a Glance 2021: OECD Indicators. Paris: OECD Publishing; 2021.
   Google Scholar
• Armitage J, Baigent C, Barnes E; Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393(10170):407–415. doi:10.1016/S0140-6736(18)31942-1
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation. 2014;129(25):S1–45. doi:10.1161/01.cir.0000437738.63853.7a
   PubMed Web of Science ®Google Scholar
• NICE Clinical Guideline. Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. London: National Clinical Guideline Centre; 2014.
   Google Scholar
• Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769–1818. doi:10.1093/eurheartj/ehr158
   PubMed Web of Science ®Google Scholar
• Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol. 1998;81(5):582–587. doi:10.1016/s0002-9149(97)00965-x
   PubMed Web of Science ®Google Scholar
• Jones PH, Davidson MH, Stein EA, et al.; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92(2):152–160. doi:10.1016/s0002-9149(03)00530-7
   PubMed Web of Science ®Google Scholar
• Farnier M. An evaluation of alirocumab for the treatment of hypercholesterolemia, Expert 441Rev. Cardiovasc Ther. 2015;13(12):1307–1323. doi:10.1586/14779072.2015.1111759
   Google Scholar
• De Backer G, Jankowski P, Kotseva K, et al. EUROASPIRE V collaborators management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019;285:135–146. doi:10.1016/j.atherosclerosis.2019.03.014
   PubMed Web of Science ®Google Scholar
• Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532–2561. doi:10.1016/S0140-6736(16)31357-5
   PubMed Web of Science ®Google Scholar
• Yusuf S, Islam S, Chow CK, et al; Prospective 450 Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011;378(9798):1231–1243. doi:10.1016/S0140-6736(11)61215-4
   PubMed Web of Science ®Google Scholar
• Börsch-Supan A, Brandt M, Hunkler C, et al; SHARE Central Coordination Team. Data resource profile: the Survey of Health, Ageing and Retirement in Europe (SHARE). Int J Epidemiol. 2013;42(4):992–1001. doi:10.1093/ije/dyt088
   PubMed Web of Science ®Google Scholar
• Martić NB, Zečević DD, Đurđević MV, et al. Comparative analysis of the use of lipid-modifying medicines in the republic of Serbia and Nordic countries in the period 2015–2017. Hospital Pharmacol. 2020;7(3):966–461 975. doi:10.5937/hpimj2003966M
   Google Scholar
• Naumovska Z, Nestorovska AK, Grozdanova A, et al. Evaluation of statin utilisation in the Republic of Macedonia during 2013–2016. Clinicoecon Outcomes Res. 2018;10:339–347. doi:10.2147/CEOR.S157842
   PubMed Web of Science ®Google Scholar
• Health Insurance Fund of Republic of Srpska. Medicines - list of indications. Available from: https://www.zdravstvo-srpske.org/files/cjenovnici/lista_ind.pdf. Accessed February 9, 2022.
   Google Scholar
• Ruokoniemi P, Helin SA, Klaukka T, Neuvonen PJ, Huupponen R. Shift of statin use towards the elderly in 1995–2005: a nation-wide register study in Finland. Br J Clin Pharmacol. 2008;66(3):405–410. doi:10.1111/j.1365-2125.2008.03258.x
   PubMed Web of Science ®Google Scholar
• Maas AH, Appelman YE. Gender differences in coronary heart disease. Neth Heart J. 2010;18(12):598–602. doi:10.1007/s12471-010-0841-y
   PubMed Web of Science ®Google Scholar
• Rodgers JL, Jones J, Bolleddu SI, et al. Cardiovascular risks associated with gender and aging. J Cardiovasc Dev Dis. 2019;6(2):19. doi:10.3390/jcdd6020019
   PubMed Web of Science ®Google Scholar
• Jackevicius CA, Tu JV, Krumholz HM, et al. Comparative effectiveness of generic atorvastatin and lipitor® in patients hospitalized with an acute coronary syndrome. J Am Heart Assoc. 2016;5:e003350. doi:10.1161/JAHA.116.003350
   PubMed Web of Science ®Google Scholar
• Mortensen MB, Falk E, Schmidt M. Twenty-year nationwide trends in statin utilisation and expenditure in Denmark. Circ Cardiovasc Qual Outcomes. 2017;10(7):e003811. doi:10.1161/CIRCOUTCOMES.117.003811
   PubMed Web of Science ®Google Scholar